Vivos Therapeutics, Inc. (VVOS) · Oct 21, 2026 · Other events

Vivos Therapeutics regains Nasdaq compliance, but risk remains

Nasdaq compliance — Complies with $2.5M equity rule; re-testing required at next periodic report

Vivos Therapeutics regained Nasdaq stockholders’ equity compliance after its SOD transaction, but must prove it again in the next periodic report.

Vivos is a medical-device and healthcare-services company built around obstructive sleep apnea treatments, now broadening that platform through its recently closed SOD transaction and related diagnostic assets. The October 21 filing mainly formalizes the result of that deal rather than introducing a new operating development.

The immediate delisting threat has been pushed back. Nasdaq determined that Vivos currently satisfies the $2.5 million stockholders’ equity requirement under Listing Rule 5550(b)(1). That is a real administrative repair, but it was already the expected consequence of the SOD closing disclosed on October 19, so today’s letter is confirmation rather than a fresh strategic surprise.

The compliance fix is capital-structure driven, not evidence of stronger operations. Vivos issued Series C preferred stock with a $12 million stated value, and expects the transaction to add more than $10 million to reported stockholders’ equity, subject to final accounting and auditor review. The filing does not show that the underlying OSA business has improved or that the SOD assets are generating revenue yet.

The listing risk remains conditional, not eliminated. Nasdaq will test the company again when it files its next periodic report; failure to evidence compliance then could still lead to a delisting notice and appeal process. 〔0〕 The preferred stock can also convert into up to 80 million common shares, subject to ownership and exchange caps, leaving meaningful dilution and accounting uncertainty around the solution.

Bottom line: This filing removes an immediate Nasdaq equity-compliance problem, but it does not resolve the underlying financial fragility. The meaningful change is temporary listing relief, while the next periodic report remains the real test.

What to watch next

Next periodic report must re-evidence stockholders’ equity compliance

Original filing on SEC EDGAR

More Vivos Therapeutics, Inc. news

Vivos Therapeutics regains Nasdaq compliance, but risk remains | VVOS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.